IND (Investigational New Drug application)
Last reviewedAn Investigational New Drug application (IND) is the submission a sponsor makes to the US FDA before starting clinical trials of a new drug or biologic in the United States. Trials may begin 30 days after the FDA receives the IND, unless the agency places the study on clinical hold.
Key facts
| Regulation | 21 CFR Part 312 |
|---|---|
| Main contents | Animal pharmacology and toxicology data, manufacturing information, and clinical protocols and investigator information |
| Ongoing obligation | An annual report; the FDA accepts a DSUR in its place |
| Broadly comparable in the EU | Clinical Trial Application (CTA) |
IND and NDA
The IND allows clinical investigation to start. The New Drug Application (NDA), or the Biologics License Application (BLA) for biologics, comes at the end of development and asks for approval to market the product.

